HCPCS Level II code C1716 denotes a non-stranded gold-198 brachytherapy source billed per source. Brachytherapy sources like gold-198 seeds are implanted to deliver localized radiation for oncologic indications, making this supply code important for procedural planning, cost accounting, and claims processing nationwide. Clarity on coding for these discrete radioactive sources affects facility charge capture and alignment with radiation oncology workflows.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and typical sites of service, reimbursement and coverage benchmarks where available, and payer-specific considerations relevant to claims submission and billing practice. The publication outlines common modifiers and billing practices, highlights points of payer variability, and summarizes available policy language. Data not available in the input is noted where appropriate. The content is intended for revenue cycle professionals, coding specialists, and radiation oncology administrators who require a national-level summary of how HCPCS Level II code C1716 is used and interpreted across major payers.